Table 1.
Pre-treatment data [either number (percent) of all dogs or median and range] including signalment, historical orthopedic or neurologic disease, clinical signs, physical examination findings, pertinent bloodwork results, thoracic limb imaging modalities, ulnar tumor cytology and histopathology results, staging diagnostic modalities, and known or suspected metastatic disease.
| Number (percent) of all dogs | Median | Range | |
|---|---|---|---|
| Age (years) | 9.4 | 1.4–13.2 | |
| Sex | |||
| Male castrated | 29 (72.5%) | ||
| Female spayed | 9 (22.5%) | ||
| Male intact | 2 (5.0%) | ||
| Breed | |||
| Golden retriever | 7 (17.5%) | ||
| Labrador retriever | 6 (15.0%) | ||
| Rottweiler | 3 (7.5%) | ||
| Mastiff | 2 (5.0%) | ||
| American Staffordshire | 2 (5.0%) | ||
| Great Dane | 2 (5.0%) | ||
| Bernese mountain dog | 2 (5.0%) | ||
| Anatolian shepherd | 2 (5.0%) | ||
| Mixed/other | 14 (35.0%) | ||
| Historical data | |||
| History of orthopedic/neurologic disease | 24 (60.0%) | ||
| Prior medical/surgical management for orthopedic/neurologic disease | 15 (37.5%) | ||
| Clinical signs | |||
| Duration of clinical signs prior to presentation to referral hospital (days) | 30 | 4–307 | |
| Thoracic limb lameness | 35 (87.5%) | ||
| Apparent pain | 29 (72.5%) | ||
| Swelling or mass effect of antebrachium | 32 (80.0%) | ||
| Non-specific signs (hyporexia, lethargy, and/or weight loss) | 6 (15.0%) | ||
| Physical examination | |||
| Vital parameters within normal limits | 40 (100.0%) | ||
| Weight | 40 | 23.6–82 | |
| Body condition score (/9)† | 5.5 | 4–9 | |
| Lameness | 31 (77.5%) | ||
| Mild lameness | 13 (32.5%) | ||
| Moderate lameness | 5 (12.5%) | ||
| Severe lameness | 4 (10.0%) | ||
| Lameness reported but not described | 9 (22.5%) | ||
| Palpable swelling or mass effect of antebrachium | 30 (75.0%) | ||
| Bloodwork | |||
| Monocyte count (/uL) | 435 | 0–1,200 | |
| Alkaline phosphatase (IU/L) | 65 | 17–722 | |
| Thoracic limb imaging | |||
| Radiographs | 39 (97.5%) | ||
| Computed tomography | 23 (57.5%) | ||
| Cytology of ulnar tumor prior to treatment ‡ | |||
| Osteosarcoma/sarcoma | 17 (42.5%) | ||
| Inconclusive | 4 (10.0%) | ||
| Histopathology of ulnar tumor prior to treatment § | |||
| Osteosarcoma | 3 (7.5%) | ||
| Chondrosarcoma | 2 (5.0%) | ||
| Sarcoma | 1 (2.5%) | ||
| Inconclusive | 1 (2.5%) | ||
| Staging diagnostics | |||
| Thoracic radiographs | 36 (90.0%) | ||
| Thoracic computed tomography | 8 (20.0%) | ||
| Abdominal ultrasound | 10 (25.0%) | ||
| Nuclear scintigraphy | 9 (22.5%) | ||
| Positron emission tomography/computed tomography | 6 (15.0%) | ||
| Additional skeletal radiographs | 12 (30.0%) | ||
| Known or suspected metastatic disease | 12 (30.0%) |
†
Data available for 18/40 dogs.
‡
Performed in 21 dogs.
§
Performed in 7 dogs.